Atherosclerosis - An inflammatory disease

New England Journal of Medicine

Volumn 340, Issue 2, 1999, Pages 115-126

  Ross, Russell ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RENIN;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHLAMYDOPHILA PNEUMONIAE; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; ENDOTHELIUM INJURY; HERPES VIRUS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNE RESPONSE; INFECTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR;

ARTERIOSCLEROSIS; BLOOD PLATELETS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; INFLAMMATION; LIPOPROTEINS, LDL; MONOCYTES; MUSCLE, SMOOTH, VASCULAR; T-LYMPHOCYTES;

EID: 0033552883     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199901143400207     Document Type: Review

References (149)

1. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Bethesda, Md.: National Heart, Lung, and Blood Institute, 1993. (NIH publication no. 93-3095.)
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
3. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
4. Breslow JL. Cardiovascular disease burden increases, NIH funding decreases. Nat Med 1997;3:600-1.
5. Braunwald E. Shattuck Lecture - cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997;337:1360-9.
6. Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 1973;180:1332-9.
7. Idem. The pathogenesis of atherosclerosis. N Engl J Med 1976;295: 369-77, 420-5.
8. Ross R. The pathogenesis of atherosclerosis - an update. N Engl J Med 1986;314:488-500.
9. Idem. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
10. Idem. Atherosclerosis: a defense mechanism gone awry. Am J Pathol 1993;143:987-1002.
11. Napoli C, D'Armiento FP, Mancini FP, et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia: intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest 1997;100:2680-90.
12. Stary HC, Chandler AB, Glagov S, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1994;89:2462-78.
13. Simionescu N, Vasile E, Lupu F, Popescu G, Simionescu M. Prelesional events in atherogenesis: accumulation of extracellular cholesterol-rich liposomes in the arterial intima and cardiac valves of the hyperlipidemic rabbit. Am J Pathol 1986;123:109-25.
14. Ross R. Atherosclerosis - a problem of the biology of arterial wall cells and their interactions with blood components. Arteriosclerosis 1981;1: 293-311.
15. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987;316:1371-5.
16. Stary HC. The histological classification of atherosclerotic lesions in human coronary arteries. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and coronary artery disease. Vol. 1. Philadelphia: Lippincott-Raven, 1996:463-74.
17. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 1986;6:131-8.
18. van der Wal AC, Das PK, Bentz van de Berg D, van der Loos CM, Becker AE. Atherosclerotic lesions in humans: in situ immunophenotypic analysis suggesting an immune mediated response. Lab Invest 1989;61:166-70.
19. Libby P, Ross R. Cytokines and growth regulatory molecules. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and coronary artery disease. Vol. 1. Philadelphia: Lippincott-Raven, 1996:585-94.
20. Raines EW, Rosenfeld ME, Ross R. The role of macrophages. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and coronary artery disease. Vol. 1. Philadelphia: Lippincott-Raven, 1996:539-55.
21. Falk E, Shah PK, Fuster V. Pathogenesis of plaque disruption. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and coronary artery disease. Vol. 2. Philadelphia: Lippincott Raven, 1996:492-510.
22. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997;272:20963-6.
23. Khoo JC, Miller E, McLoughlin P, Steinberg D. Enhanced macrophage uptake of low density lipoprotein after self-aggregation. Arteriosclerosis 1988;8:348-58.
24. Khoo JC, Miller E, Pio F, Steinberg D, Witztum JL. Monoclonal antibodies against LDL further enhance macrophage uptake of LDL aggregates. Arterioscler Thromb 1992;12:1258-66.
25. Navab M, Berliner JA, Watson AD, et al. The Yin and Yang of oxidation in the development of the fatty streak: a review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1996;16:831-42.
26. Morel DW, Hessler JR, Chisholm GM. Low density lipoprotein cytotoxicity induced by free radical peroxidation of lipid. J Lipid Res 1983;24: 1070-6.
27. Griendling KK, Alexander RW. Oxidative stress and cardiovascular disease. Circulation 1997;96:3264-5.
28. Han J, Hajjar DP, Febbraio M, Nicholson AC. Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36. J Biol Chem 1997;272:21654-9.
29. Diaz MN, Frei B, Vita JA, Keaney JF Jr. Antioxidants and atherosclc rotic heart disease. N Engl J Med 1997;337:408-16.
30. Falcone DJ, McCaffrey TA, Vergilio JA. Stimulation of macrophage urokinase expression by polyanions is protein kinase C-dependent and requires protein and RNA synthesis. J Biol Chem 1991;266:22726-32.
31. - production in the pig coronary artery. Circulation 1997;96:3593-601.
32. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Nad Acad Sci USA 1987;84:2995-8.
33. Rajavashisth TB, Andalibi A, Territo MC, et al. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 1990;344:254-7.
34. Leonard EJ, Yoshimura T. Human monocyte chemoattractant protein-1 (MCP 1). Immunol Today 1990;11:97-101.
35. Stopeck AT, Nicholson AC, Mancini FP, Hajjar DP. Cytokine regulation of low density lipoprotein receptor gene transcription in HepG2 cells. J Biol Chem 1993;268:17489-94.
36. Hajjar DP, Haberland ME. Lipoprotein trafficking in vascular cells: molecular Trojan horses and cellular saboteurs. J Biol Chem 1997;272:22975-8.
37. Geng Y-J, Libby P. Evidence for apoptosis in advanced human atheroma: colocalization with interleukin 1 beta-converting enzyme. Am J Pathol 1995;147:251-66.
38. Palkama T. Induction of interleukin-1 production by ligands binding to the scavenger receptor in human monocytes and the THP-1 cell line. Immunology 1991;74:432-8.
39. Palkama T, Matikainen S, Hurme M. Tyrosine kinase activity is involved in the protein kinase C induced expression of interleukin-1 beta gene in monocytic cells. FEBS Lett 1993;319:100-4.
40. Ylä-Herttuala S, Palinski W, Rosenfeld ME, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989;84:1086-95.
41. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci U S A 1987;84:7725-9.
42. Kita T, Nagano Y, Yokode M, et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci U S A 1987; 84:5928-31.
43. Sasahara M, Raines EW, Chait A, et al. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation? J Clin Invest 1994;94:155-64.
44. Chang MY, Sasahara M, Chait A, Raines EW, Ross R. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. II. Cellular composition and proliferation. Arterioscler Thromb Vasc Biol 1995;15:1631-40.
45. Fruebis J, Gonzalez V, Silvestre M, Palinski W. Effect of probucol treatment on gene expression of VCAM-1, MCP-1, and M-CSF in the aortic wall of LDL receptor-deficient rabbits during early atherogenesis. Arterioscler Thromb Vasc Biol 1997;17:1289-302.
46. Reaven PD, Khouw A, Beltz WF, Parthasarathy S, Witztum JL. Effect of dietary antioxidant combinations in humans: protection of LDL by vitamin E but not by beta-carotene. Arterioscler Thromb 1993;13:590-600.
47. Rimm EB, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993;328:1450-6.
48. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993;328:1444-9.
49. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study. Lancet 1996;347:781-6.
50. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;334:1145-9.
51. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150-5.
52. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-28.
53. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet 1985; 37:1-31.
54. Nehler MR, Taylor LM Jr, Porter JM. Homocysteinemia as a risk factor for atherosclerosis: a review. Cardiovasc Surg 1997;6:559-67.
55. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-6.
56. Malinow MR. Plasma homocyst(e)ine and arterial occlusive diseases: a mini-review. Clin Chem 1995;41:173-6.
57. Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976;58:731-41.
58. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993;91:2873-9.
59. Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease: enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997;17:2074-81.
60. Upchurch GR Jr, Welch GN, Fabian AJ, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997;272:17012-7.
61. Verhoef P, Stampfer MJ. Prospective studies of homocysteine and cardiovascular disease. Nutr Rev 1995;53:283-8.
62. Omenn GS, Beresford SAA, Motulsky AG. Preventing coronary heart disease: B vitamins and homocysteine. Circulation 1998;97:421-4.
63. Chobanian AV, Dzau VJ. Renin angiotensin system and atherosclerotic vascular disease. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and cor onary artery disease. Vol. 1. Philadelphia: Lippincott-Raven, 1996:237-42.
64. Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia: autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest 1992;90: 456-61.
65. Lacy F, O'Connor DT, Schmid-Schönbein GW. Plasma hydrogen peroxide production in hypertensives and normotensive subjects at genetic risk of hypertension. J Hypertens 1998;16:291-303.
66. Swei A, Lacy F, DeLano FA, Schmid-Schönbein GW. Oxidative stress in the Dahl hypertensive rat. Hypertension 1997;30:1628-33.
67. Vanhoutte PM, Boulanger CM. Endothelium dependent responses in hypertension. Hypertens Res 1995;18:87-98.
68. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation 1997;96:4095-103.
69. Hendrix MG, Salimans MM, van Boven CP, Bruggeman CA. High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis. Am J Pathol 1990;136:23-8.
70. Jackson LA, Campbell LA, Schmidt RA, et al. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis. Am J Pathol 1997;150:1785-90.
71. Thom DH, Wang SP, Grayston JT, et al. Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease. Arterioscler Thromb 1991;11:547-51.
72. Melnick JL, Adam E, Debakey ME. Cytomegalovirus and atherosclerosis. Eur Heart J 1993;14:Suppl K:30-8.
73. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96:404-7.
74. Hajjar DP, Fabricant CG, Minick CR, Fabricant J. Virus induced atherosclerosis: herpesvirus infection alters aortic cholesterol metabolism and accumulation. Am J Pathol 1986;122:62-70.
75. Nicholson AC, Hajjar DP. Herpesviruses in atherosclerosis and thrombosis: etiologic agents or ubiquitous bystanders? Arterioscler Thromb Vasc Biol 1998;18:339-48.
76. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997;350:430-6.
77. Gotlieb AI, Langille BL. The role of theology in atherosclerotic coronary artery disease. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and coronary artery disease. Vol. 1. Philadelphia: Lippincott-Raven, 1996:595-606.
78. Springer TA, Cybulsky MI. Traffic signals on endothelium for leukocytes in health, inflammation, and atherosclerosis. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and coronary artery disease. Vol. 1. Philadelphia: Lippincott-Raven, 1996:511-38.
79. Muller WA, Weigl SA, Deng X, Phillips DM. PECAM-1 is required for transendothelial migration of leukocytes. J Exp Med 1993;178:449-60.
80. Giachelli CM, Lombardi D, Johnson RJ, Murry CE, Almeida M. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am J Pathol 1998;152:353-8.
81. Nagel T, Resnick N, Atkinson WJ, Dewey CF Jr, Gimbrone MA Jr. Shear stress selectively upregulates intercellular adhesion molecule-1 expression in cultured human vascular cndothelial cells. J Clin Invest 1994;94:885-91.
82. Resnick N, Collins T, Atkinson W, Bonthron DT, Dewey CF Jr, Gimbrone MA Jr. Platelet-derived growth factor B chain promoter contains a cis-acting fluid shear-stress-responsive element. Proc Natl Acad Sci U S A 1993;90:4591-5.
83. Lin MC, Almus-Jacobs F, Chen HH, et al. Shear stress induction of the tissue factor gene. J Clin Invest 1997;99:737-44.
84. Mondy JS, Lindner V, Miyashiro JK, Berk BC, Dean RH, Geary RL. Platelet-derived growth factor ligand and receptor expression in response to altered blood flow in vivo. Circ Res 1997;81:320-7.
85. McMillan DE. Blood flow and the localization of atherosclerotic plaques. Stroke 1985;16:582-7.
86. Nakashima Y, Raines EW, Plump AS, Breslow JL, Ross R. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler Thromb Vasc Biol 1998; 18:842-51.
87. Boring L, Gosling J, Chensue SW, et al. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest 1997;100:2552-61.
88. Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest 1998;101:353-63.
89. Hynes RO, Wagner DD. Genetic manipulation of vascular adhesion molecules in mice. J Clin Invest 1996;98:2193-5.
90. Herren B, Raines EW, Ross R. Expression of a disintegrin-like protein in cultured human vascular cells and in vivo. FASEB J 1997;11:173-80.
91. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumor-necrosis factor-α from cells. Nature 1997;385:729-33.
92. Moss ML, Jin S-LC, Milla ME, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour necrosis factor-α. Nature 1997;385:733-6.
93. De Caterina R, Basta G, Lazzerini G, et al. Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:2646-54.
94. Hwang S-J, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1997;96:4219-25.
95. Rosenfeld ME, Ross R. Macrophage and smooth muscle cell proliferation in atherosclerotic lesions of WHHL and comparably hypercholesterolemic fat-fed rabbits. Arteriosclerosis 1990;10:680-7.
96. Hansson GK, Libby P. The role of the lymphocyte. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and coronary artery disease. Vol. 1. Philadelphia: Lippincott-Raven, 1996:557-68.
97. Hansson GK, Jonasson L, Seifert PS, Stemme S. Immune mechanisms in atherosclerosis. Arteriosclerosis 1989;9:567-78.
98. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1995;92:3893-7.
99. Folcik VA, Aamir R, Cathcart MK. Cytokine modulation of LDL oxidation by activated human monocytes. Arterioscler Thromb Vasc Biol 1997;17:1954-61.
100. Wick G, Romen M, Amberger A, et al. Atherosclerosis, autoimmunity, and vascular-associated lymphoid tissue. FASEB J 1997;11:1199-207.
101. Hollenbaugh D, Mischel-Petty N, Edwards CP, et al. Expression of functional CD40 by vascular endothelial cells. J Exp Med 1995;182:33-40.
102. Mach F, Schönbeck U, Bonnefoy J-Y, Pober JS, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation 1997;96:396-9.
103. Schönbeck U, Mach F, Sukhova GK, et al. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? Circ Res 1997;81:448-54.
104. Schönbcck U, Mach F, Bonnefoy JY, Loppnow H, Flad H-D, Libby P. Ligation of CD40 activates interleukin 1β-converting enzyme (caspase-1) activity in vascular smooth muscle and endothelial cells and promotes elaboration of active interleukin 1β. J Biol Chem 1997;272:19569-74.
105. Mach F, Schönbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998; 394:200-3.
106. 3 integrin, and GPIbα. J Exp Med 1998;187:329-39.
107. Davies MJ. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation 1990;82:Suppl II:II-38-II-46.
108. Badimon JJ, Meyer B, Feigen LP, et al. Thrombosis triggered by severe arterial lesions is inhibited by oral administration of a glycoprotein IIb/IIIa antagonist. Eur J Clin Invest 1997;27:568-74.
109. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest 1991;64:5-15.
110. Ross R, Fuster V. The pathogenesis of atherosclerosis. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and coronary artery disease. Vol. 1. Philadelphia: Lippincott Raven, 1996:441-60.
111. Maher JJ. Hepatic fibrosis caused by alcohol. Semin Liver Dis 1990; 10:66-74.
112. Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheuer PJ, Sobin LH. The morphology of cirrhosis: definition, nomenclature, and classification. Bull World Health Organization 1977;55:521-40.
113. Sewell KL, Trentham DE. Pathogenesis of rheumatoid arthritis. Lancet 1993;341:283-6.
114. Harris ED Jr. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 1990;322:1277-89.
115. Johnson RJ. What mediates progressive glomerulosclerosis? The glomerular endothelium comes of age. Am J Pathol 1997;151:1179-81.
116. Magil AB, Cohen AH. Monocytes and focal glomerulosclerosis. Lab Invest 1989;61:404-9
117. Kuhn C III, Boldt J, King TE Jr, Crouch E, Vartio T, McDonald JA. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis 1989;140:1693-703.
118. Lukacs NW, Ward PA. Inflammatory mediators, cytokines, and adhesion molecules in pulmonary inflammation and injury. Adv Immunol 1996; 62:257-304.
119. Brody AR, Soler P, Basset F, Haschek WM, Witschi H. Epithelial-mesenchymal associations of cells in human pulmonary fibrosis and in BHT-oxygen-induced fibrosis in mice. Exp Lung Res 1981;2:207-20.
120. Sarles H, Bernard JP, Johnson C. Pathogenesis and epidemiology of chronic pancreatitis. Annu Rev Med 1989;40:453-68.
121. DiMagno EP, Layer P, Clain JE. Chronic pancreatitis. In: Go VLW, DiMagno EP, Gardner JD, Lebenthal E, Reber HA, Scheele GA, eds. The pancreas: biology, pathobiology, and disease. 2nd ed. New York: Raven Press, 1993:665-706.
122. Tormey VJ, Faul J, Leonard C, Burke CM, Dilmec A, Poulter LW. T-cell cytokines may control the balance of functionally distinct macrophage populations. Immunology 1997;90:463-9.
123. Garlanda C, Dejana E. Heterogeneity of endothelial cells: specific markers. Arterioscler Thromb Vasc Biol 1997;17:1193-202.
124. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994;90:2126-46.
125. Lee RT, Libby P. The unstable atheroma. Arterioscler Thromb Vasc Biol 1997;17:1859-67.
126. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-503.
127. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-41.
128. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
129. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C reactive protein and risk of coronary events in stable and unstable angina: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997;349:462-6.
130. Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. Circulation 1997;96:4204-10.
131. Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in 'active' coronary artery disease. Am J Cardiol 1990;65:168-72.
132. Levenson J, Giral P, Razavian M, Gariepy J, Simon A. Fibrinogen and silent atherosclerosis in subjects with cardiovascular risk factors. Arterioscler Thromb Vasc Biol 1995;15:1263-8.
133. Topouzis S, Majesky MW. Smooth muscle lineage diversity in the chick embryo: two types of aortic smooth muscle cell differ in growth and receptor-mediated transcriptional responses to transforming growth factorβ. Dev Biol 1996;178:430-45.
134. Frid MG, Aldashev AA, Dempsey EC, Stenmark KR. Smooth muscle cells isolated from discrete compartments of the mature vascular media exhibit unique phenotypes and distinct growth capabilities. Circ Res 1997; 81:940-52.
135. Chamley-Campbell JH, Campbell GR, Ross R. Phenotype-dependent response of cultured aortic smooth muscle to serum mitogens. J Cell Biol 1981;89:379-83.
136. Babaev VR, Bobryshev YV, Stenina OV, Tararak EM, Gabbiani G. Heterogeneity of smooth muscle cells in atheromatous plaque of human aorta. Am J Pathol 1990;136:1031-42.
137. Koyama H, Raines EW, Bornfeldt KE, Roberts JM, Ross R. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell 1996;87:1069-78.
138. Assoian RK, Marcantonio EE. The extracellular matrix as a cell cycle control element in atherosclerosis and restenosis. J Clin Invest 1996;98: 2436-9.
139. Mercurius KO, Morla AO. Inhibition of vascular smooth muscle cell growth by inhibition of fibronectin matrix assembly. Circ Res 1998;82: 548-56.
140. Wesley RB II, Meng X, Godin D, Galis ZS. Extracellular matrix modulates macrophage functions characteristic to atheroma: collagen type I enhances acquisition of resident macrophage traits by human peripheral blood monocytes in vitro. Arterioscler Thromb Vasc Biol 1998;18:432-40.
141. Smith RE, Hogaboam CM, Stricter RM, Lukacs NW, Kunkel SL. Cell-to-cell and cell-to-matrix interactions mediate chemokine expression: an important component of the inflammatory lesion. J Leukoc Biol 1997;62: 612-9.
142. Shalon D, Smith SJ, Brown PO. A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization. Genome Res 1996;6:639-45.
143. DeRisi J, Penland L, Brown PO, et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 1996;14:457-60.
144. Ramsay G. DNA chips: state-of-the-art. Nat Biotechnol 1998;16:40-4.
145. Chien KR. Genes and physiology: molecular physiology in genetically engineered animals. J Clin Invest 1996;97:901-9.
146. Plump AS, Smith JD, Hayek T, et al. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 1992;71:343-53.
147. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 1994;14:133-40.
148. Qiao J-H, Tripathi J, Mishra NK, et al. Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am J Pathol 1997;150:1687-99.
149. de Villiers WJS, Smith JD, Miyata M, Dansky HM, Darley E, Gordon S. Macrophage phenotype in mice deficient in both macrophage-colony-stimulating factor (op) and apolipoprotein E. Arterioscler Thromb Vasc Biol 1998;18:631-40.